Organovo Holdings, Inc. (ONVO)
NASDAQ: ONVO · IEX Real-Time Price · USD
0.931
-0.139 (-12.98%)
At close: May 1, 2024, 4:00 PM
0.960
+0.029 (3.09%)
After-hours: May 1, 2024, 7:51 PM EDT
Organovo Holdings Revenue
Organovo Holdings had revenue of $242.00K in the twelve months ending December 31, 2023, down -85.83% year-over-year. Revenue in the quarter ending December 31, 2023 was $5.00K, a -96.18% decrease year-over-year. In the fiscal year ending March 31, 2023, Organovo Holdings had annual revenue of $370.00K, a decrease of -75.33%.
Revenue (ttm)
$242.00K
Revenue Growth
-85.83%
P/S Ratio
44.72
Revenue / Employee
$13,444
Employees
18
Market Cap
10.61M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 370.00K | -1.13M | -75.33% |
Mar 31, 2022 | 1.50M | - | - |
Mar 31, 2021 | 0 | - | - |
Mar 31, 2020 | 2.20M | -895.00K | -28.96% |
Mar 31, 2019 | 3.09M | -1.51M | -32.85% |
Mar 31, 2018 | 4.60M | 373.00K | 8.82% |
Mar 31, 2017 | 4.23M | 2.75M | 185.23% |
Mar 31, 2016 | 1.48M | 912.00K | 159.72% |
Mar 31, 2015 | 571.00K | 192.00K | 50.66% |
Mar 31, 2014 | 379.00K | -818.00K | -68.34% |
Dec 31, 2012 | 1.20M | 228.00K | 23.53% |
Dec 31, 2011 | 969.00K | 366.00K | 60.70% |
Dec 31, 2010 | 603.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Centogene | 55.72M |
IM Cannabis | 54.72M |
Zhongchao | 17.23M |
Biotricity | 11.63M |
RedHill Biopharma | 6.53M |
Fresh2 Group | 2.35M |
Elevai Labs | 1.71M |
Nexalin Technology | 110.75K |
ONVO News
- 16 days ago - Organovo's fatty liver disease drug meets main goal in mid-stage study - Reuters
- 16 days ago - Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo - GlobeNewsWire
- 3 months ago - Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress - GlobeNewsWire
- 4 months ago - Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress - GlobeNewsWire
- 5 months ago - Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results - GlobeNewsWire
- 6 months ago - CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan - GlobeNewsWire
- 6 months ago - Organovo Highlights FXR314 Combination Therapy Potential and Plan - GlobeNewsWire
- 8 months ago - Organovo to Participate in the H.C. Wainwright Global Investment Conference - GlobeNewsWire